- platform. In June 2016
Genentech partnered Epizyme to
conduct clinical trials exploring whether Epizyme's EZH2
inhibitor tazemetostat would be synergistic...
- Spindler. In
August 2022,
Ipsen successfully completed the
acquisition of
Epizyme and its lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free...
-
inhibits other DNA methyltransferases. EPZ005687 In 2012, a
company called Epizyme revealed EPZ005687, an S-adenosylmethionine (SAM)
competitive inhibitor...
- and
orphan drug designation. The FDA
granted the
approval of
Tazverik to
Epizyme Inc. "FDA
approves first treatment option specifically for
patients with...
-
Howard Hughes Medical Institute 2007–2013
Founder and
scientific advisor of
Epizyme, Cambridge, MA 1999–2012 ****istant
Professor to
Kenan Distinguished Professor...
- [citation needed]
Editas Medicine,
Eikon Therapeutics,
Element Biosciences,
Epizyme, Evonetix,
Intarcia Therapeutics, Inscripta, Immunomedics,
Intellia Therapeutics...
- a
member of the
Scientific Advisory Board at T2Biosystems, Inc. and at
Epizyme, Inc. He was a
founding co-editor of the
Annual Review of
Cancer Biology...
